Search

Your search keyword '"S. Ozyilmaz"' showing total 9 results
Start Over Author "S. Ozyilmaz" Search Limiters Available in Library Collection
Sorry, I don't understand your search. ×
9 results on '"S. Ozyilmaz"'

1. Evaluation of cardiac injury with biomarkers and echocardiography after COVID-19 infection

Author

M, Gul, S, Ozyilmaz, Z, Bastug Gul, C, Kacmaz, and M H, Satilmisoglu

Subjects
C-Reactive Protein, Heart Diseases, Troponin T, Echocardiography, COVID-19, Humans, Stroke Volume, Biomarkers, Ventricular Function, Left
Abstract

Coronavirus disease 2019 (COVID-19) causes cardiovascular damage in the acute period. Knowledge regarding cardiovascular damage after COVID-19 infection and during longer-term follow-up is currently limited. In our study, we aimed to compare cardiac and inflammatory markers and echocardiographic parameters between patients who had recovered from COVID-19 and control group. A total of 224 individuals were included, comprising 126 patients with a history of COVID-19 and 98 healthy controls. The demographic characteristics of the two groups were similar. Complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), N-terminal pro-B type natriuretic peptide (NT-ProBNP), D-dimer, haemoglobin A1C, troponin T and creatine kinase myocardial band (CK-MB) levels were compared between both groups. The mean follow-up period of the COVID-19 group was 58.39 ± 39.1 days (range:10 - 180 days post-COVID-19). Red cell distribution width (RDW), ESR, CRP, NT-ProBNP, D-dimer and troponin T values were significantly higher in the COVID-19 group compared to the control group. Left ventricular ejection fraction (LVEF) was significantly lower in the COVID-19 group. Left ventricular diastolic diameter (LVDD) and incidence of pericardial effusion were higher in the COVID-19 group. For multivariate analysis, possible factors identified by univariate analysis were subjected to multivariate logistic regression analysis to determine independent predictors of COVID-19. Among these factors, RDW, CRP and LVEF were independently higher in the COVID-19 group than in the control group. We conclude that although the clinical and prognostic significance of cardiac and other inflammatory markers in the acute phase of COVID-19 is known, we found that these biomarkers and echocardiography parameters can also be used in the follow-up of cardiac injury for a mid-term period post-infection.

Published
2022

2. Real-life data for major adverse cardiac events in patients with ST-elevation myocardial infarction prasugrel versus ticagrelor

Author

M H, Satilmisoglu, M, Gul, S, Ozyilmaz, and A Y, Cizgici

Subjects
Ticagrelor, Percutaneous Coronary Intervention, Treatment Outcome, Humans, ST Elevation Myocardial Infarction, Prospective Studies, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors
Abstract

We aimed to evaluate the major adverse cardiac events and other clinical outcomes in ST-segment-elevation myocardial infarction (STEMI) cases treated with prasugrel versus ticagrelor after percutaneous intervention (PCI). The study was a prospective comparative study into which 560 patients diagnosed with STEMI, being suitable for PCI, and prescribed with either prasugrel (n = 232) or ticagrelor (n = 328) as oral antiplatelet therapy were included. Patients were followed up for a mean of 10.9 ± 4.7 months and 11.9 ± 4.9 months for prasugrel and ticagrelor groups, respectively. The major adverse cardiac events developed in similar rates between prasugrel and ticagrelor groups (7.3% versus 7.9%, respectively, p = 0.793). Even if mortality rate was higher in ticagrelor group, the difference did not reach statistically significance (3.4% vs. 6.7%, p=0.092). Among all study population, stent thrombosis and minor bleeding was recorded only in 7 (1.2%) and 12 (2.1%) patients without significant difference between prasugrel and ticagrelor groups. Twenty patients (8.6%) in prasugrel group and 47 patients (14.3%) in ticagrelor group discontinued treatment (p = 0.023). In ticagrelor group, 12 patients discontinued treatment due to dyspnea, but none in prasugrel group (p = 0.001). Prasugrel and ticagrelor have similar effects on major adverse cardiac events in patients with STEMI undergoing primary PCI, but prasugrel seems more tolerated and less discontinued than ticagrelor.

Published
2021

3. Poster session Friday 13 December - PM: 13/12/2013, 14:00-18:00 * Location: Poster area

Author

A. Rojek, M. Bekbossynova, J. Onaindia, R. Ferrer Lopez, B. Javani, A. Sharif-Rasslan, N. Al, R. Davies, U. Ikeda, R. Ferreira, A. Cincin, M. Plewka, F. Weidemann, B. Fadel, O. Akgul, Z. Frikha, M. Haghjoo, J. Jensen, G. Agoston, M. Sunbul, R. Strasser, M. Pepi, Y. Fuku, M. Minamisawa, J. Holm, O. Dzikowska Diduch, Y. Pya, J. Macancela Quinones, P. Gaudron, G. Ertl, S. Thivolet, C. Koukoulis, H. Yun, S. Iancovici, D. Capodanno, M. Barthelet, A. Medeiros-Domingo, T. Le Tourneau, A. P. Lee, G. Derumeaux, I. Rodriguez, B. Naegeli, S. Rahmatullah, A. Bayes, H. Schaff, A. M. Caggegi, C. Zito, M. D'alto, R. Favilli, J. Baan, M. Aydin, J. Bonaque Gonzalez, A. Akhundova, I. Cruz, R. Karpov, H. Okura, D. Dequanter, M. T. Grillo, A. Ingvarsson, S. Prasad, A. Dahiya, U. Rosenschein, G. Sinagra, J. Kochanowski, M. Niemann, Y. Saijo, B. Bouma, K. Sveric, Y. Topilsky, M. Ministeri, J. Piek, C. Marinescu, M. Bilik, I. Ikuta, M. Al-Admawi, C. Araujo, D. Trifunovic, S. Onciul, G. Pavlidis, F. Ruiz Lopez, M. Oyumlu, C. Kenny, F. Kayan, C. Ginghina, R. Piatkowski, I. Lekuona Goya, A. Almeida, G. Portugal, H. Motoki, M. Cinteza, B. Seifert, S. Lee, M. Banovic, T. Sakakura, A. Pappalardo, B. Stuart, Y. Chuyasova, T. Yamanaka, N. Roche, C. Wunderlich, X. Arana, L. Ernande, V. Ribeiro, Y. Tanabe, L. Vazdar, Y. Tayyareci, E. Malev, M. Eren, J. Gil, S. Lunghetti, D. Krieger, S. Mangiafico, M. Izumo, D. Cacela, A. Kovacs, A E Van Den Bosch, E. Reffo, P. G. Jorgensen, O. Dubourg, J. Abreu, S. Wang, E. Cervesato, K. Theodoropoulos, N. Ozaydogdu, L. Jung, Y. Kijima, E. Ostenfeld, C. Corsi, M. Florescu, M. Chenilleau, K. Yokota, A. Faeh-Gunz, R. Winter, J. Dreyfus, D. Kang, S. K. Saha, S. Surdulli, L. Abikeyeva, M. Marchel, P. Meregalli, M. Yamat, X. Arana Achaga, C. Shahla, V. Palicka, M. Tanaka, A. Galrinho, K. Endo, M. Saravi, J. Bogaert, H. Oeygarden, S. Okabe, J. Reiken, G. Ionescu, C. Selton-Suty, A. Nunes-Diogo, E. S. Davidsen, E. Kinova, A. Bandeira, Y. Seo, S. Hojberg, G. Siblini, M. Pellegrino, M. Ostojic, J. J. Onaindia Gandarias, M. Pereira, F. Antonini-Canterin, F. Akturk, T. Nakajima, M. Al Fayyadh, S. Herrmann, G. Stellin, M. E. Menting, B. Sasko, J. Song, T. Kurokawa, F. Dipasqua, T. Maruo, M. Geleijnse, H. Triantafyllidi, M. Komeda, R. Praus, V. Nesvetov, M. Fineschi, A. Auricchio, M. Dorobantu, A. Degirmencioglu, E. Laraudogoitia Zaldumbide, S. Velasco Del Castillo, Z. Marcetic, U. Waje-Andreassen, F. Fang, K. Farsalinos, L. Vasina, D. Muraru, M. Faludi, P. Rio, S. Peppes, T. Karaahmet, G. Suermeci, P. Maccarthy, S. Kotsovilis, Y. Akashi, G. Di Salvo, Z. Issa, J. Gibbs, A. Poletti, E. Bonnefoy-Cudraz, A. Madej-Pilarczyk, E. Gerdts, K. Solymossy, P. Kogoj, T. Tomita, M. Lisi, K. Suzuki, S. Sifakis, E.A. Surkova, T. Fritz-Hansen, V. Tritakis, E. Romeo, T. Akesson-Lindow, B. Lasota, A. Florian, M. Maciel, K. Gieszczyk-Strozik, M. Imazio, S. Ozyilmaz, K. Kadota, V. Peric, E. Zencirci, B. Tzvetkov, U. Aguirre Larracoechea, D. Caldeira, Y. Motoyoshi, M. Russo, R. Suri, H. Pintaric, O. Celik, D. Himbert, L. Branco, B. Sun, S. Dzhetybayeva, A. Esen Zencirci, M. Ciurzynski, R. Nunyez, B. Iung, K. Takenaka, A. S. Omran, K. Ozden, J. Argacha, S. Pradel, A. M. Pistritto, M. Pfyffer, C. Dedobbeleer, J. Vojacek, P. Costa, E. Albuquerque, A. Tamadoni, B. Sarubbi, M. Carlsson, R. Mogelvang, G. Oria, K. Kimura, E. Kim, F. Kousathana, A. Mateescu, A. Varga, J. Clerc, M. Noni, S. Kyrzopoulos, S. Andossova, S. Almeida, E. Shkolnik, J. Koyama, M. Daimon, S. Saeed, B. Popescu, M. Tigen, R. Wennemann, C. Venner, M. Guazzi, R. Magalhaes, H. Hayashi, M. Salagianni, A. Kiotsekoglou, A. Baggiano, C. Chao, T. Nakao, H. Becher, R. Zeppellini, J. Marrugat, G. Erente, P. Lancellotti, R. Rimbas, D. M'barek, M. Cameli, Y. Katahira, S. Carerj, C. Grasso, P. Moulin, D. Lavergne, B. Merkely, D. Mahoney, C. Tamburino, W. Kosmala, G. Romagna, T. Potpara, T. Ha, R. Biffanti, C. Dundar, E. Gunyeli, L. Weinert, R. Dworakowski, A. Ferreira, T. Biering-Sorensen, H. Engblom, M. Erturk, G. Varlan, M. Ikeda, L. Thorell, S Von Bardeleben, S. Palomar, K. Boerlage-Van Dijk, T. Ishizu, S. Stoerk, I. Germanakis, H. Yamamoto, Q. Shang, A. Borizanova, C. Fiorentini, R. Candinas, U. Inci, F. Macedo, O. Huttin, R. Pudil, I. D. Gabric, C. Silveira, I. Sari, V. Lambadiari, L. Laczmanski, E. Timofeev, A. Izgi, D. Bravo Bustos, K. Wierzbowska-Drabik, P. Masci, H. Pusuroglu, F. Navarro Garcia, P. Adhikari, K. Mizia-Stec, S. Celik, A. Medressova, S. Pala, R. Retkoceri, O. Tautu, S. Tzikas, S. Ohtsuki, T. Akbulut, S. Goliszek, K. Mitsudo, P. Palczewski, A. Spyrou, K. Filipiak, I. Tzoulaki, A. Erdem, M. Krupa, K. Yoshida, M. Polovina, J. Vanoverschelde, H. Pereira, K. Obase, O. V. Tereshina, J. Liebeton, L. Petrescu, W. Gin-Sing, T. A. Warsame, B. Lichodziejewska, M. Takeuchi, J. Cuypers, Y. Jung, E. Martins, S. Mondillo, D. Liu, D. Planinc, I. Subirana, S. Shahrzad, U. Richter, M. Prull, C.H. Attenhofer Jost, E. Alfonzetti, A. Kosztin, V. Carvalho, M. van Bracht, K. Shahgaldi, M. Altman, A. Cacicedo, R. Dulgheru, M. Arslan, L. Dell'angela, M. De Biasio, J. Roos-Hesselink, A. Sawant, B. Ghadrdoust, H. Tabuchi, I. Rangel, M. Aguado Martin, L. Pedro-Botet, K. Koch, G. Zugazabeitia Irazabal, I. Hausmanowa-Petrusewicz, A. Werther-Evaldsson, A. Korshunova, Q. Zhang, A. Anton Ladislao, C. Bergerot, F. Karlsen, T. Akagi, M. Jasinski, I. Komuro, A. Apor, L. Fourcade, P. Argiento, E. Zemtsovsky, A. Correra, J. Chudek, S. Choi, G. Barletta, A. Varela, A. Manouras, H. Oe, A. D'andrea, S. Ramezani, M. Akil, A. Azevedo, S. Imme, A. Ionac, E. Saracoglu, K. Nakagawa, O. Vinter, S. Reeva, G. Van Camp, T. Forster, T. Butz, I. Ikonomidis, A. Costa, M. Ruiz Lopez, D. Vinereanu, G. Opolski, K. Akay, A. Vrublevsky, J. Silva Marques, L. Sousa, F. D'ascenzi, N. Oprescu, F. Veronesi, A. Mysiak, R. Dan, M. Nobre Menezes, D. Kim, V. Vida, Y. Kim, V. Di Bello, D. Sharif, A. I. Nagy, A. Sikora-Puz, H. Moladoust, C. Florescu, M. Kostrubiec, L. Pierard, E. Ural, A. Goncalves, K. Grudzka, A. Charalampopoulos, A. Luycx-Bore, M. Wilkins, S. Mushtaq, D. Messika-Zeitoun, N. Olsen, C. Mornos, M. Tesic, R. Symons, S. Bekbossynov, H. Erer, M. Kokorina, I. Joao, C. Cotrim, D. Voilliot, M. Yamawaki, N. Roszczyk, J. Inamo, C. Sousa, A. Porto, I. Lekakis, A. G. Caelian, D. Rigopoulos, T. Komori, G. Pontone, S. Scandura, F. Melao, N. Toh, A. Neikova, V. Aboyans, S. La Carrubba, D. Zamfir, S. Dymarkowski, J. Magne, G. Szeplaki, S. Velasco, J. Mcghie, M. Losito, L. Shkolnik, M. Petrovic, I. Papadakis, D. Brito, I. Schilling, O. Bech-Hanssen, M. Enriquez-Sarano, C. Lafaras, O. Enescu, B. Bijnens, R. Lang, C. Lestuzzi, C. Kirma, N. Vallejo, F. Elmkies, M. Vasatova, N. Uslu, M. Yuksel, M. Anastasiou-Nana, G. Gatti, O. Milanesi, V. Donghi, A. Kozuka, C. Henri, K. Tsimopoulou, G. Karakus, A. Cerutti, J. Macancela Quinonez, E. Laraudogoitia, P. Unger, A. Roijer, K. Kurnicka, M. Carasi, D. Djikic, M. Dragovic, H. Aksu, S. Srivatsa, A. Khan, N. Maschietto, D. Cozma, V. Andreakos, C. Meurling, O. Wendler, C. Doulaptsis, E. Aliot, T. Damy, Z. Ojaghihaghighi, L. Mateu, S. Knop, M. Vis, M. Mizia, A. Khalil, E. Abate, M. Gomez Recio, J. Ko, M. Seo, D. Tsiapras, E. Tekbas, C. Celeng, K. Aonuma, M. Przewlocka-Kosmala, S. Laaraibi, T. Sahin, D. Mohty, P. Jorgensen, A. Fiarresga, C. Scharf, E. Conte, V. Pergola, C. Jons, M. Padalino, R. Krecki, M. Malicse, F. Parthenakis, N. Bolivar Herrera, G. Foldes, O. Vriz, J. Kasprzak, S. Janssens, H. Bejiqi, H. Nakajima, R. Naeije, E. Papadavid, A. Subinas, R. Calabro, M. Trbusic, W. Tomkowski, M. Ooshima, A N Vachev, A. Fotaki, E. Brochet, F. Scholz, A. Boshchenko, P. Massoure, S. Munoz Troyano, J. Zumalde, M. Tsakalou, E. Bertella, M. Carminati, A. Kalkan, Y. Miyashita, I. Comanescu, A. M. Esen, K. Nakamura, A. Sanchez Espino, G. Berkenboom, H. Trappe, B. Castaldi, M. Cielecka-Prynda, Y. Otsuji, R. Bejiqi, E. Caiani, A. Moreo, P. Vaida, J. Castillo, S. Stankovic, C. Davos, H. Murata, T. Komiya, K. Berta, A. Aussoleil, A. Yildiz, B. Piamonti, K. Sato, J. Silva-Cardoso, I. Popescu, R. Pap, A. Serafin, K. Addetia, F. Olsen, J. Cautela, C. Yu, R. El Mahmoud, C. Cardoso, N. Echahidi, V. Pyankov, T. Yamada, R. Hoffmann, H. Johno, L. Lopes, R. Li, R. Onut, J. Lekakis, G. Nicolosi, N. Watanabe, Y. Basaran, A. Matos, A. Chmiel, N. Host, M. Sabria, N. Gronkova, P. Hulek, H. Cakmak, E. Wiegerinck, A. Goudev, A. Romero Pereiro, A. Pellegrini, L. Badano, P. Cameli, N. Abdullah, M. Deja, A. Ekmekci, A. Vahanian, A. Retkoceri, V. Mor-Avi, H. Ito, N. Bindraban, T. Rigo, R. Vanderpool, N. Mansencal, M. K. Tigen, J. Bech, H. Thibault, A. Pshepiy, A. Decker-Bellaton, L. Saghy, Z. Al Bulbul, G. Generati, I. Nedeljkovic, Y. Kuatbayev, G. A. Derumeaux, M. Varoudi, Y. Juilliere, K. Uno, P. Virot, B.M. van Dalen, M. Witsenburg, E. Yamashita, K. Okada, E. Gomez, P. Pinto-Teixeira, T. Yambe, N. Preumont, K. Hu, R. Jalalian, A. Formenti, M. Monaghan, P. Pruszczyk, L. Massa, D. Andreini, A. Fromm, E. Stoupel, D. Ural, R. Pilliere, L. Llobera, W. Kim, M. Sobczak, F. Bandera, S. Oliveira, P. Mills, H. Zemir, E. Oner, S. Sparla, C. Cosgrove, S. Kou, A. Annoni, B. Vujisic-Tesic, M. Hojati, L. Carr, P. Meimoun, A. Jaccard, E. Varotto, N. Bulj, T. Kawata, M. Bulut, G. Dimitriadis, B. Ramondo, V. Voudris, H. Christensen, H. Eguchi, J. Grapsa, P. R. Silva Fazendas Adame, C. Cimadevilla, L. Christensen, M. Cikes, A. Izawa, G. Merchan Ortega, A. Makrigiannakis, M. Forkmann, G. Radegran, P. Dias, A. Faiz, C. Stefopoulos, Y. Vasyuk, A. Akyol, L. Howard, A. Correia, J. Younger, and C. Greis

Subjects
medicine.medical_specialty, business.industry, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, General Medicine, Session (computer science), Cardiology and Cardiovascular Medicine, business
Published
2013
Full Text
View/download PDF

4. Evaluation of cardiac injury with biomarkers and echocardiography after COVID-19 infection.

Author

Gul M, Ozyilmaz S, Bastug Gul Z, Kacmaz C, and Satilmisoglu MH

Subjects
Biomarkers, C-Reactive Protein metabolism, Echocardiography, Humans, Stroke Volume, Troponin T, Ventricular Function, Left, COVID-19, Heart Diseases diagnosis, Heart Diseases virology
Abstract

Coronavirus disease 2019 (COVID-19) causes cardiovascular damage in the acute period. Knowledge regarding cardiovascular damage after COVID-19 infection and during longer-term follow-up is currently limited. In our study, we aimed to compare cardiac and inflammatory markers and echocardiographic parameters between patients who had recovered from COVID-19 and control group. A total of 224 individuals were included, comprising 126 patients with a history of COVID-19 and 98 healthy controls. The demographic characteristics of the two groups were similar. Complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), N-terminal pro-B type natriuretic peptide (NT-ProBNP), D-dimer, haemoglobin A1C, troponin T and creatine kinase myocardial band (CK-MB) levels were compared between both groups. The mean follow-up period of the COVID-19 group was 58.39 ± 39.1 days (range:10 - 180 days post-COVID-19). Red cell distribution width (RDW), ESR, CRP, NT-ProBNP, D-dimer and troponin T values were significantly higher in the COVID-19 group compared to the control group. Left ventricular ejection fraction (LVEF) was significantly lower in the COVID-19 group. Left ventricular diastolic diameter (LVDD) and incidence of pericardial effusion were higher in the COVID-19 group. For multivariate analysis, possible factors identified by univariate analysis were subjected to multivariate logistic regression analysis to determine independent predictors of COVID-19. Among these factors, RDW, CRP and LVEF were independently higher in the COVID-19 group than in the control group. We conclude that although the clinical and prognostic significance of cardiac and other inflammatory markers in the acute phase of COVID-19 is known, we found that these biomarkers and echocardiography parameters can also be used in the follow-up of cardiac injury for a mid-term period post-infection.

Published
2022
Full Text
View/download PDF

5. Real-life data for major adverse cardiac events in patients with ST-elevation myocardial infarction prasugrel versus ticagrelor.

Author

Satilmisoglu MH, Gul M, Ozyilmaz S, and Cizgici AY

Subjects
Humans, Platelet Aggregation Inhibitors adverse effects, Prasugrel Hydrochloride adverse effects, Prospective Studies, Ticagrelor adverse effects, Treatment Outcome, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction drug therapy
Abstract

We aimed to evaluate the major adverse cardiac events and other clinical outcomes in ST-segment-elevation myocardial infarction (STEMI) cases treated with prasugrel versus ticagrelor after percutaneous intervention (PCI). The study was a prospective comparative study into which 560 patients diagnosed with STEMI, being suitable for PCI, and prescribed with either prasugrel (n = 232) or ticagrelor (n = 328) as oral antiplatelet therapy were included. Patients were followed up for a mean of 10.9 ± 4.7 months and 11.9 ± 4.9 months for prasugrel and ticagrelor groups, respectively. The major adverse cardiac events developed in similar rates between prasugrel and ticagrelor groups (7.3% versus 7.9%, respectively, p = 0.793). Even if mortality rate was higher in ticagrelor group, the difference did not reach statistically significance (3.4% vs. 6.7%, p=0.092). Among all study population, stent thrombosis and minor bleeding was recorded only in 7 (1.2%) and 12 (2.1%) patients without significant difference between prasugrel and ticagrelor groups. Twenty patients (8.6%) in prasugrel group and 47 patients (14.3%) in ticagrelor group discontinued treatment (p = 0.023). In ticagrelor group, 12 patients discontinued treatment due to dyspnea, but none in prasugrel group (p = 0.001). Prasugrel and ticagrelor have similar effects on major adverse cardiac events in patients with STEMI undergoing primary PCI, but prasugrel seems more tolerated and less discontinued than ticagrelor.

Published
2021
Full Text
View/download PDF

6. The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy.

Author

Ozyilmaz S, Akgul O, Uyarel H, Pusuroglu H, Gul M, Satilmisoglu MH, Bolat I, Ozyilmaz I, Uçar H, Yildirim A, and Bakir I

Subjects
Death, Sudden, Cardiac epidemiology, Female, Humans, Leukocyte Count, Male, Middle Aged, Prospective Studies, Risk Assessment, Cardiomyopathy, Hypertrophic blood, Lymphocytes, Neutrophils
Abstract

Introduction: Previous studies have demonstrated the predictive value of the neutrophil-to-lymphocyte ratio (NLR) in many cardiovascular disorders. The aim of this study was to assess whether NLR is associated with echocardiographic or electrocardiographic parameters, or with predicted five-year risk of sudden cardiac death (SCD), in patients with hypertrophic cardiomyopathy (HCM)., Methods: This prospective observational study included 74 controls and 97 HCM patients. Three years of follow-up results for HCM patients were evaluated., Results: NLR was significantly higher in patients with fragmented QRS, ventricular tachycardia, and presyncope than in those without (p=0.031, 0.030, and 0.020, respectively). NLR was significantly higher in patients whose predicted five-year risk of SCD was more than 6% and whose corrected QT interval was greater than 440 ms (p=0.022 and 0.001, respectively). It was also significantly higher in patients whose left ventricular ejection fraction (LVEF) was <60% than in those with LVEF >60% (p=0.017)., Conclusion: NLR was significantly higher in patients with HCM compared to the control group. A high NLR is associated with a higher five-year risk of SCD in patients with HCM., (Copyright © 2017 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.)

Published
2017
Full Text
View/download PDF

7. Catecholaminergic Polymorphic Ventricular Tachycardia: A Rare Cause of Cardiac Arrest Following Blunt Chest Trauma.

Author

Ozyilmaz I, Ozyilmaz S, Ergul Y, Akdeniz C, and Tuzcu V

Abstract

Unlabelled: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an electrophysiological disorder of a physically normal heart that occurs in children when the body is subjected to intense emotional or physical stress that causes adrenergic discharge. This troubling disease can be sporadic (spontaneous) or familial (genetic/inherited). Unfortunately, its associated ventricular tachycardia may cause sudden death, so early diagnosis of CPVT is very important. Treatment modalities include medical treatment, implantation of a cardioverter defibrillator, or surgical sympatectomy; but the implantable cardioverter defibrillator (ICD) should be the first choice in patients with a history of cardiac arrest. We herein present the case of a patient diagnosed with CPVT after a successful cardiopulmonary resuscitation triggered by blunt chest trauma. We implanted an implantable cardioverter defibrillator and started oral B-blocker treatment. During the course of follow-up, flecainide was added to his treatment depending on the patient's status regarding recurrent ICD shock. The patient has now continued follow-up without recurrent ICD shock since flecainide treatment was initiated. In conclusion, in patients with syncope and sudden cardiac arrest secondary to physical stress or blunt chest trauma, CPVT should be considered and an implantable cardioverter defibrillator must be implanted. Additionally, flecainide theraphy should be considered to decrease recurrent ICD shock., Key Words: Blunt chest trauma; Cardiac arrest; CPVT.

Published
2015
Full Text
View/download PDF

8. Holter electrocardiography findings and P-wave dispersion in pediatric patients with transcatheter closure of atrial septal defects.

Author

Ozyilmaz I, Ozyilmaz S, Tola HT, Saygi M, Kiplapinar N, Tanıdır C, Ergul Y, Guzeltas A, and Odemis E

Subjects
Child, Female, Follow-Up Studies, Heart physiopathology, Humans, Male, Pediatrics methods, Treatment Outcome, Arrhythmias, Cardiac diagnosis, Electrocardiography, Ambulatory methods, Heart Septal Defects, Atrial surgery, Postoperative Complications diagnosis, Septal Occluder Device
Abstract

Background: This study aimed to determine the frequency of postintervention arrhythmia and factors associated with the development of arrhythmia, including the correlation between arrhythmia and P-wave dispersion, and the effects of the latter on transcatheter closure of atrial septal defects (ASDs)., Methods: Holter ECG recordings were performed before and after the intervention and 6 and 12 months later in 47 of the 59 patients who had undergone transcatheter ASD closure and once in the healthy control subjects., Results: A statistically significant correlation was identified between the patients' arrhythmia grade according to Lown's system and each of the following: the number of defects, the size of the atrioventricular valve rim, the presence of an atrial septal aneurysm., Conclusion: The frequency of arrhythmia increases after transcatheter ASD closure, gradually decreases within the next year, and is most frequently of a benign nature. Lown's arrhythmia grading of patients occluded with either the Amplatzer septal occluder (ASO) or the Cardio-O-Fix septal occluder (CSO) were compared, and the arrhythmia frequency was higher with the latter. One day after the intervention, the P maximum (Pmax ) and the P dispersion(Pdis ) values were not increased but in fact slightly reduced in patients occluded with either ASO or CSO. An improvement in the electrical system resulting from early anatomical and mechanical healing following transcatheter ASD occlusion may explain the reduction in the Pmax and Pdis values., (©2013, Wiley Periodicals, Inc.)

Published
2014
Full Text
View/download PDF

9. Effects of long intubation period on respiratory functions following open heart surgery.

Author

Akdur H, Polat MG, Yiğit Z, Arabaci U, Ozyilmaz S, and Gürses HN

Subjects
Aged, Female, Humans, Male, Middle Aged, Physical Therapy Modalities, Postoperative Period, Respiratory Function Tests, Retrospective Studies, Time Factors, Vital Capacity, Cardiac Surgical Procedures, Intubation, Lung physiopathology, Respiration
Abstract

The objective of the present study was to compare pre- and postoperative pulmonary function tests in adult patients who had intubation periods greater and less than 24 hours following elective open heart surgery. Group 1 consisted of 91 patients (18 females and 73 males) gr, whose intubation periods were more than 24 hours (mean: 8.1+/-18.6 hours); and group 2 75 patients (13 females and 62 males) who had intubation periods less than 24 hours (mean: 13.25+/-3.60 hours). The pulmonary function test measurements were obtained from a vitalograph before and after the operation (just before being discharged from the hospital), All patients underwent cardiopulmonary physiotherapy and a rehabilitation programme during their hospital stay. The patients were similar in height and weight. The duration of hospitalization of the patients who had a prolonged intubation period was 17.26+/-9.7 days, while that of the control group was 10.64+/-2.04 days (P<0.0001). When the preoperative pulmonary function test values of each patient were compared with the expected values, the percent values of forced expiratory volume for one second, flow velocity of the mid-forced expiration and forced expiratory flow which were achieved by group 2 were significantly high compared to those of group 1 (P=0.014, P= 0.03 and P<0.0001, respectively). However, the percent values of forced vital capacity were similar. When the percent variations of the differences between the pre- and postoperative pulmonary function test values of the groups were compared, all values except the flow velocity of the mid-forced expiration, and forced vital capacity, were found to be significantly lower statistically in the group having a prolonged intubation period. As a result, it was determined that the patients whose preoperative pulmonary function test values were poor, had longer intubation periods and similarly, they continued to be worse after the operation. We believe that it is advantageous to apply more intensive pulmonary rehabilitation for prolonged periods to these patients in the postoperative period.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results